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What is already known on this topic?
Low-dose computed tomography (LDCT) screening for lung cancer is re-
commended for current and former smokers meeting eligibility criteria. As
of 2017, rural areas generally had less geographic access to LDCT screen-
ing than urban areas.
What is added by this report?
Despite the recent proliferation of LDCT screening, rural areas in Missouri
and Illinois have low levels of access to screening. We observed no associ-
ation between geographic access to screening and lung cancer mortality.
What are the implications for public health practice?
As LDCT screening becomes more widespread, future studies need to eval-




Low-dose computed tomography (LDCT) lung cancer screening is
recommended for current and former smokers who meet eligibil-
ity criteria. Few studies have quantitatively examined disparities in
access to LDCT screening. The objective of this study was to ex-
amine relationships between 1) rurality, sociodemographic charac-
teristics, and access to LDCT lung cancer screening and 2) screen-
ing access and lung cancer mortality.
Methods
We used census block group and county-level data from Missouri
and Illinois. We defined access to screening as presence of an ac-
credited screening center within 30 miles of residence as of May
2019. We used mixed-effects logistic models for screening access
and county-level multiple linear regression models for lung can-
cer mortality.
Results
Approximately 97.6% of metropolitan residents had access to
screening, compared with 41.0% of nonmetropolitan residents.
After controlling for sociodemographic characteristics, the odds of
having access to screening in rural areas were 17% of the odds in
metropolitan areas (95% CI, 12%–26%). We observed no associ-
ation between screening access and lung cancer mortality. South-
eastern Missouri, a rural and impoverished area, had low levels of
screening access, high smoking prevalence, and high lung cancer
mortality.
Conclusion
Although access to LDCT is lower in rural areas than in urban
areas, lung cancer mortality in rural residents is multifactorial and
cannot be explained by access alone. Targeted efforts to imple-
ment rural LDCT screening could reduce geographic disparities in
access, although further research is needed to understand how in-
creased access to screening could affect uptake and rural disparit-
ies in lung cancer mortality.
Introduction
Low-dose computed tomography (LDCT) screening has increased
the ability to detect early-stage lung cancer in recent years (1). The
National Lung Screening Trial showed that LDCT screening re-
duces risk of lung cancer death by up to 20%, compared with chest
x-ray (1). In light of this evidence, the US Preventive Services
Task Force (USPSTF) issued a recommendation to provide annu-
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al LDCT screening to adults aged 55 to 80 who have at least a 30
pack-year smoking history, currently smoke or quit in the past 15
years, and have no lung cancer symptoms (2). Medicare sub-
sequently began reimbursing screening of adults aged 55 to 77 (2).
Unique among cancer screenings, LDCT reimbursement is contin-
gent on provision of smoking cessation counseling and shared de-
cision making, both of which are also billable services (2).
The burden of these requirements on physician practices, along
with the high rate (>95%) of false-positive test results (1), may ex-
plain why screening rates are low. Although the number of accred-
ited LDCT centers nationwide increased from an estimated 203 in
2014 to 1,748 in early 2017 (3), a study of 10 geographically di-
verse US states found that 12.7% of adults aged 55 to 80 met
USPSTF criteria for LDCT screening in 2017, but of these adults,
only 12.5% reported receiving screening in the previous year (4).
Barriers to LDCT screening persist — rural residents nationwide
have less access, defined as distance and driving time, to LDCT
screening than their urban counterparts (3,5). Although more than
95% of adults aged 55 to 79 in 8 northeastern states (Connecticut,
Delaware, Maryland, Massachusetts, New Jersey, New York,
Pennsylvania, Rhode Island) have access to a screening center
within 30 miles (Euclidean distance), the proportion in the Midw-
est (Illinois, Indiana, Iowa,  Kansas, Michigan, Minnesota, Mis-
souri, Nebraska, North Dakota, Ohio, South Dakota, Wisconsin) is
lower and highly variable (22%–93%) (3).
Our investigation focused on Missouri and Illinois, both Midwest-
ern states in the upper Mississippi Delta, a region marked by high
cancer mortality (6). Missouri and Illinois are home to 6.1% of the
US population and contain a heterogeneous mix of geographies,
from densely populated cities to rural farmland. Both states reflect
the nationwide pattern of higher smoking prevalence in rural areas
than in urban areas (7).
The 2 states have significantly different policies on health care and
tobacco. Illinois was an early expander of Medicaid under the Af-
fordable Care Act, whereas Missouri was not. The state cigarette
tax is more than 15 times higher in Illinois ($2.98/pack) than in
Missouri ($0.17/pack) (8). Demographically, Missouri has a high-
er proportion of rural residents than the United States as a whole
(29.6% for Missouri vs 19.3% nationwide), whereas Illinois, at
11.5%, has a lower proportion (9). A study published in 2018
identified Missouri as a state with moderate access to LDCT
screening and high lung cancer mortality and Illinois as a state
with high access to screening and moderate mortality (3).
Given rural–urban differences and the importance of using precise
and localized estimates to drive public health priorities (10), we
performed a detailed analysis of screening access in Missouri and
Illinois. Efforts to reduce rural–urban disparities in LDCT screen-
ing and lung cancer mortality require county-specific information
on screening “deserts” and mortality hotspots (6). As such, the
primary objective of this study was to identify locations in Mis-
souri and Illinois that have high lung cancer mortality and/or ci-
garette smoking rates but low levels of access to LDCT screening;
these locations are priority areas for intervention. We built on pre-
vious work (5) by using multilevel, mixed-effects modeling to
quantify the association between rurality, sociodemographic char-
acteristics, and access to screening at the census block group level.
Additionally, a secondary objective was to conduct an exploratory




We collected and organized data by using methods similar to those
of Eberth et al (3). In May 2019, we obtained addresses of screen-
ing centers accredited by the American College of Radiology (11)
and Lung Cancer Alliance (now GO2 Foundation for Lung Can-
cer) Screening Centers of Excellence (12). We compiled ad-
dresses for 356 centers in Missouri, Illinois, and all neighboring
states (Arkansas, Indiana, Iowa, Kansas, Kentucky, Michigan,
Nebraska, Oklahoma, Tennessee, Wisconsin). We collected ad-
dresses from neighboring states because patients may cross state
lines to reach the nearest center. When multiple screening centers
were located on a single hospital campus, we randomly chose 1
center. Additionally, we removed from analysis 1 center in Indi-
ana that was closed. We performed automatic geocoding in Arc-
GIS Desktop version 10.6 using the USA Geocoding Service
(Esri). We used interactive rematch for screening centers that
matched equally well to multiple street addresses.
We manually rematched all unmatched centers and centers
matched to a zip code rather than a street address (n = 56 centers)
by using a Google Maps API (application programming interface;
https://developers.google.com/maps/documentation/geocoding/intr
o). Consistent with the methods of Eberth et al, we constructed a
30-mile planar buffer around each screening center to represent
the area in which that center was deemed accessible (3). A nation-
wide study comparing driving distance and straight-line distance
from all census tracts to the closest hospital found that the 2 meas-
ures are highly correlated in the absence of shorelines, mountains,
or other physical barriers (13). Missouri and Illinois contain few
such barriers; thus, we felt justified in using a 30-mile straight-line
buffer. Hospital “deserts” are defined by the lack of a hospital
within a 30-mile radius (14). Consistent with Eberth et al, we con-
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sidered a center accessible to residents of census block groups
whose centroids lay inside the buffer (3).
We used these data to calculate the county-wide percentage of res-
idents aged 55 to 79 who have access to LDCT screening within
30 miles. We obtained census block group–level data on age from
American Community Survey (ACS) 2013–2017 five-year estim-
ates (15). Of the available categories, the age group 55 to 79 was
the closest option to the recommended screening age range of 55
to 80 (15).
Measures
Screening access measure. We dichotomized access to LDCT
screening at the census block group–level as presence or absence
of at least 1 center within 30 miles of the centroid. At the county
level, we quantified access by the proportion of adults aged 55 to
79 who lived in a census block group and met this criterion. Be-
cause appropriate data on smoking status were unavailable, we as-
sumed that the ratio of adults aged 55 to 79 to LDCT-eligible
adults was roughly constant across all census block groups in a
county.
Rurality measures. We used census tract–level rural–urban com-
muting area (RUCA) codes to measure rurality (16). For model-
ing purposes, we grouped codes 1 to 3 as metropolitan, codes 4 to
6 as micropolitan, and codes 7 to 10 as small town/rural areas.
However, because lung cancer mortality data were available only
at the county level, we used the National Center for Health Statist-
ics (NCHS) county-level classification (17) for our exploratory
mortality model. NCHS codes range from 1 (large central metro)
to 6 (noncore). We used RUCA codes for our main access model
because they provide more fine-grained information than NCHS
codes on rurality in a census tract and its census block groups.
Sociodemographic characteristics. We obtained demographic
census block group–level data from ACS 2013–2017 five-year es-
timates (15). We defined income as median annual household in-
come (in thousands of dollars), education as percentage of resid-
ents aged 25 or older with at least a college degree, and race as the
percentage of White residents and the percentage of African
American residents.
Lung cancer and smoking measures. We obtained county-level,
age-adjusted lung and bronchus cancer mortality rates during
2013–2017 from the National Cancer Institute’s Surveillance, Epi-
demiology, and End Results (SEER) program via SEER*Stat soft-
ware version 8.3.6 (18). We used mortality rates (per 100,000) for
people aged 60 or older. Given the lead-time bias and additional
survival time after lung cancer diagnosis, we believed mortality in
this age range was most likely to be affected by a screening pro-
gram for people aged 55 to 80. We suppressed data from 1 county
in Missouri because of a small number (<10) of deaths. We ob-
tained data on 2019 adult smoking prevalence from County Health
Rankings (19). We classified adults as smokers if they reported
currently smoking every day or most days and having smoked at
least 100 cigarettes in their lifetime.
Map development. We obtained census block group shapefiles
from the Census Bureau (15) and state-level and county-level
shapefiles from Esri (20). We created categories by rounding quin-
tiles to the nearest 10% for access to screening, nearest 10 per
100,000 for lung cancer mortality, and nearest 0.5% for smoking
prevalence. Mortality and smoking quintiles were based on nation-
al (rather than bi-state) data, to emphasize how Illinois and Mis-
souri compare with other states. We created maps in ArcGIS
Desktop version 10.6 (Esri).
Statistical analysis
For the first analysis, our outcome of interest was access to screen-
ing within 30 miles of the census block group centroid (binary).
Predictor variables were rurality as quantified by RUCA codes
(main predictor; categorical), income (continuous), education
(continuous), and race (continuous). We used multilevel, mixed-
effects logistic regression modeling to determine the association
between outcome and predictor variables. In this model, the
census block group was the unit of analysis. We defined RUCA
codes at the census tract level; all other variables were defined at
the census block group level.
Our modeling procedure was as follows: first, we considered
bivariate logistic models to examine crude associations between
screening access and each predictor. We then used the full addit-
ive model with all predictor variables (fixed effects) and random
intercepts for each state and county. Counties were nested within
states. Census tract was not considered a random effect because of
the small number of census block groups in some tracts. We then
tested models involving interaction terms and random slopes for
various predictors. These terms were all nonsignificant and thus
not included in the final model. We calculated the odds ratio (OR),
95% CI, and P value associated with each fixed-effect parameter.
Our second, exploratory model used the county as the unit of ana-
lysis. We sought to determine the association between access to
LDCT screening, defined as the proportion of residents aged 55 to
79 whose census block group of residence is located within 30
miles of a screening center (main predictor), and lung cancer mor-
tality rate in adults aged 60 or older (outcome). Other covariates
included adult smoking prevalence, rurality (NCHS code), in-
come, education, race, and state in which the county is located.
We used multiple linear regression modeling for this county-level
analysis. We defined all variables at the county level, and all vari-
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ables except NCHS code were continuous. Because only 3
counties in the study area were designated as large central metro
(level 1), we performed a sensitivity analysis using a dichotom-
ized rurality variable (levels 1–4 [all metro area counties] vs levels
5–6 [micropolitan and noncore]).
For both analyses, all tests were 2-sided and P < .05 was con-
sidered significant. We calculated variance inflation factors to as-
sess evidence of multicollinearity. For the main mixed-effects
model, we assessed county-level random intercepts for normality.
For the multiple regression model, we checked residual plots for
normality and constant variance. We performed statistical ana-
lyses in R version 3.6.1 (The R Project for Statistical Computing).
Results
Overall, 91.2% of Illinois residents aged 55 to 79 and 78.3% of
their Missouri counterparts were within 30 miles of an LDCT
screening center. Areas with low access to screening correspon-
ded roughly to the states’ most rural regions (Figure 1). These
areas of low access included central northern Missouri, the
Bootheel region in southeastern Missouri, and southern Illinois
(Figure 2A). LDCT screening centers in Illinois and Missouri
were located in census block groups whose residents were more
likely than residents in the 2-state region as a whole to identify as
White (76.6% vs 67.6%) and have at least a college degree (45.1%
vs 31.8%). Similarly, weighted median income in census block
groups containing screening centers was $72,222, compared with
$57,750 across all census block groups.
Figure 1. Measures of rurality in Missouri and Illinois and location of low-dose
computed tomography screening centers. A, Rural–urban commuting area
(RUCA) categories at the census tract level, determined by US Department of
Agriculture Economic Research Service (16). B, National Center for Health
Statistics (NCHS) rural–urban classification codes at the county level (17).
Data on screening centers obtained from American College of Radiology (11)
and GO2 Foundation for Lung Cancer (12). Shapefiles obtained from ESRI
(20).
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Figure 2. Access to LDCT lung cancer screening, lung cancer mortality, and
smoking prevalence in Missouri and Illinois. A, Percentage of residents aged
55–79 with access to an LDCT lung cancer screening center within 30 miles.
B, Lung cancer mortality (deaths per 100,000) among adults aged ≥60. C,
Adult smoking prevalence. All maps are at the county level, and categories are
based on rounded quintiles. Data obtained from American College of
Radiology (11),  GO2  Foundation for  Lung Cancer (12),  Surveillance,
Epidemiology, and End Results program (18), and County Health Rankings
(19). Shapefiles from ESRI (20). Abbreviation: LDCT, low-dose computed
tomography.
Both states had pockets of high lung cancer mortality, although
smoking rates were consistently higher in Missouri than in Illinois
(Figure 2B and 2C). Southeastern Missouri had the highest con-
centration of both lung cancer mortality and adult smokers.
In metropolitan area cores or nearby commuting areas (RUCA
codes 1–3), 97.6% of residents had access to LDCT screening,
compared with 41.0% of residents in micropolitan or small town/
rural areas (codes 4–10). This difference in access was similar
across NCHS county-level codes (Table 1). Furthermore, as rural-
ity increased, we observed higher rates of adult smoking and lung
cancer mortality among adults aged 60 or older.
The mixed-effects logistic regression model of access to LDCT
screening within a 30-mile radius achieved convergence, and a
likelihood ratio test showed that inclusion of random effects signi-
ficantly improved fit (χ2 = 3417.6; df = 2; P < .001). Small town
and rural census block groups had significantly lower adjusted
odds than metropolitan census block groups of access to screen-
ing within a 30-mile radius (OR = 0.17; 95% CI, 0.12–0.26) (Ta-
ble 2). Screening access in micropolitan areas was similarly lower
than in metropolitan areas (OR = 0.17; 95% CI, 0.10–0.27).
In the county-level models, we found no significant relationship
between access to LDCT screening and lung cancer mortality after
adjusting for smoking prevalence, rurality, and demographic char-
acteristics (P = .68) (Table 3). The variables most strongly associ-
ated with lung cancer mortality per 100,000 residents were
smoking prevalence (β = 9.7; 95% CI, 4.6 to 14.9), percentage of
population aged 25 or older with a college degree (β = −2.7; 95%
CI, −1.5 to −3.9), and residence in Missouri (β = −41.2; 95% CI,
−68.2 to −14.2). Thus, a 1 percentage-point increase in smoking
prevalence was associated with a mortality increase of 9.7 per
100,000 residents, and a 1 percentage-point increase in the frac-
tion of individuals aged 25 or older with a college degree was as-
sociated with a decrease of 2.7 per 100,000. Rurality and other
variables showed no association, and use of a binary rurality vari-
able (all metropolitan vs micropolitan/noncore) yielded nearly
identical results.
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Discussion
Our study examined access to LDCT screening across diverse urb-
an and rural areas, and in communities of varying sociodemo-
graphics. The odds of urban populations having access to screen-
ing were more than 5 times greater than those of micropolitan or
rural counterparts. After adjusting for smoking prevalence and
demographic characteristics, we found no evidence that greater ac-
cess to screening or greater urbanization is associated with lower
county-level lung cancer mortality. However, counties with a lar-
ger proportion of college-educated residents or lower smoking
prevalence tended to have lower lung cancer mortality.
Several studies reported that rural residents have lower access to
LDCT screening (3,5,21), and our study confirms those findings.
Our study also found that micropolitan areas have no better access
than rural areas. Findings from our study reveal a negligible asso-
ciation between access to LDCT screening and lung cancer mor-
tality rates.
Most likely, the observed lack of association between access to
screening and mortality was due to the nascent state of LDCT
screening and low uptake during the years of mortality data used
in our study (2013–2017) (4). Screening can detect early-stage and
slow-growing cancers that would not have otherwise been diag-
nosed for quite some time. Because lung cancer tends to be diag-
nosed at late stages with poor survival rates, several years of high-
er rates of screening may be needed before reduced mortality is
seen. The overall delay from screening implementation to de-
crease in mortality roughly equals the sum of lead-time bias (ap-
proximately 1–3 years for LDCT) (22) and the traditional (without
screening) survival time. Other variables may have affected our
mortality analysis. In Illinois, a major coal-producing state, resid-
ential proximity to coal mines is associated with increased lung
cancer incidence and mortality (23). Regardless, our analysis rep-
resents valuable baseline research and demonstrates the import-
ance of attending to county-level disparities. An increase in LD-
CT screening uptake would likely reduce lung cancer mortality at
the population level. On the basis of colorectal cancer screening
research, we believe that greater geographic access to LDCT
screening could effectively increase uptake (24). Improving geo-
graphic access to a service with low uptake is still worthwhile, be-
cause poor access may be contributing to low uptake.
Although rural areas are associated with poorer health outcomes
than urban areas (25), we must also consider the urban–rural para-
dox, which suggests that among urban residents, greater distance
to health care facilities is inversely associated with receiving care,
but among rural residents, greater distance is positively associated
with receiving care (26). Using 2015 data, Odahowski et al found
that LDCT screening uptake was similar across metropolitan and
nonmetropolitan counties, although low rates in both areas (<4%)
make it difficult to understand why uptake is similar and whether
the similarity will be maintained over time (27). The similarity in
screening uptake rates may result from selection bias: the few
people who completed screening may be the most enthusiastic and
well-resourced patients in both urban and rural areas. Increased
geographic access to LDCT screening may be needed to further in-
crease uptake in rural areas. Further studies using discriminate,
comprehensive measures of access and uptake are needed to ex-
plore whether geographic availability of screening has a different
effect on mortality in urban and rural areas.
Previous research on geographic access to LDCT screening is
minimal. To our knowledge, ours is the first study to assess ac-
cess to LDCT screening, associated demographic determinants,
and implications for mortality at  a local population level.
However, our study has several limitations. First, limited availabil-
ity of public data necessitated the use of variables from 2 different
periods. Demographic and lung cancer mortality data were from
2013–2017, whereas data on smoking prevalence and access to
screening were from 2019. Second, we used data from multiple
sources, including telephone surveys, online surveys, and govern-
ment registries. Each source has its own limitations and can con-
tribute to biased model estimates. Third, the ecological study
design based on census block group–level and county-level data
precludes extensive application of our conclusions about the rela-
tionships between rurality, access, and mortality to any 1 person.
Fourth, in our exploratory analysis, county-level rates of access to
LDCT screening were based on all residents aged 55 to 79, regard-
less of smoking status or other screening eligibility criteria. By
taking this approach, we assumed that the percentage of residents
aged 55 to 79 who meet eligibility criteria was roughly constant
within a county; we made no assumptions about differences
between counties. Finally, we included in our analyses only GO2
Foundation Screening Centers of Excellence and American Col-
lege of Radiology accredited centers. Thus, our analyses may have
underestimated the proportion of residents, especially in rural
areas, who had access to some form of screening. However, ac-
credited LDCT programs may deliver a better level of care than
nonaccredited programs (28).
This study underscores the need for further research and creative
solutions for increasing LDCT screening in rural areas, especially
in the Mississippi Delta region, where significant cancer disparit-
ies exist. Not doing so may propagate the urban–rural disparities
that exist in other cancer screening programs, such as mammo-
graphy (25). Further research may be especially important in areas
with high rates of smoking and lung cancer mortality, such as
southeastern Missouri. In the past few years, mobile LDCT
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screening has been introduced in dozens of rural communities in
Georgia and Tennessee (29). Incorporation of telemedicine could
also circumvent the difficulty of finding qualified on-site special-
ists to interpret LDCT scans and recommend treatment in rural
areas. Teleradiology is now a ubiquitous practice, allowing radi-
ologists to bill for LDCT and other interpretations furnished off-
site. Some teleoncology programs offer remote interpretation of
biopsy specimens (30), which is occasionally required as a follow-
up to LDCT screening. Additionally, screening must be coupled
with effective smoking cessation interventions to maximize reduc-
tions in mortality.
Finally, our results emphasize the need for data-driven, locally tar-
geted programs to increase screening and decrease mortality. In
Missouri and Illinois, many areas with high rates of smoking and
lung cancer mortality have low access to screening. However,
some areas with high rates of smoking and lung cancer mortality,
such as the rural counties north of Kansas City, have good access
to screening. State or national one-size-fits-all programs to simply
add more screening centers may not be helpful in these communit-
ies.
Our study adds to the growing body of evidence on urban–rural
disparities in access to screening, while exploring the effects of ac-
cess to LDCT screening on lung cancer mortality. County-specific
approaches are needed to increase access to screening in rural
areas with high mortality. At the same time, further implementa-
tion research is needed to understand how to effectively minimize
individual and system-level barriers to rural screening.
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Tables
Table 1. Lung Cancer Screening Access Within 30 Miles, Adult Smoking Prevalence, and Age-Adjusted Lung Cancer Mortality, by Urban–Rural Designations, Mis-













Large central metro 3 1,378,581 (30.6) 100.0 15.2 214
Large fringe metro 30 1,524,652 (33.8) 98.6 16.0 226
Medium metro 16 351,843 (7.8) 96.4 18.4 244
Small metro 25 416,522 (9.2) 89.3 18.2 250
Micropolitan 46 418,276 (9.3) 42.8 19.2 269
Noncore 97 421,917 (9.4) 34.9 20.0 277
a Determined by National Center for Health Statistics (17).
b Based on 2013–2017 data (15).
c Based on 2019 data on screening center location (11,12). Proportion of population whose census block group of residence is within 30 miles of a screening cen-
ter; computed as averages of county-level data weighted by number of residents aged 55–79 (as of 2013–2017).
d Based on 2019 data (19). Proportion of adults who currently smoke and have smoked ≥100 cigarettes in their lifetime; computed as averages of county-level
data weighted by number of adult residents (as of 2013–2017).
e Based on 2013–2017 data (18). Rate per 100,000 population; computed as averages of county-level data weighted by number of residents aged ≥60 (as of
2013–2017).
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Table 2. Census Block Group–Level (N = 13,834 Census Block Groups) Association Between Degree of Rurality (in 2019) and Access to Lung Cancer Screening
Within 30 Miles (in 2019) Adjusted for Demographic Characteristics, Missouri And Illinois, 2013–2017
Model Parameter
Unadjusted Model Adjusted Model
OR (95% CI) P Value OR (95% CI) P Value
Degree of ruralitya
Metropolitan (RUCA codes 1–3) 1.00 [Reference] 1.00 [Reference]
Micropolitan (RUCA codes 4–6) 0.019 (0.016–0.022) <.001 0.17 (0.10–0.27) <.001
Small town or rural (RUCA codes 7–10) 0.017 (0.015–0.020) <.001 0.17 (0.12–0.26) <.001
Demographic characteristicsb
Median annual household income, in thousands, $c 1.03 (1.03–1.03) <.001 1.01 (1.00–1.02) .09
Percentage of population aged ≥25 with a college degreed 1.05 (1.05–1.06) <.001 1.01 (1.00–1.03) .08
Percentage of population that is Whited 0.91 (0.91–0.92) <.001 1.02 (1.00–1.03) .05
Percentage of population that is African Americand 0.95 (0.94–0.96) <.001 1.01 (0.99–1.03) .32
Abbreviations: OR, odds ratio; RUCA, rural–urban commuting area.
a Census tract–level RUCA codes used to measure rurality (16).
b Determined by American Community Survey 5-year estimates (15).
c Odds ratio represents $1,000 increase in median annual household income.
d Odds ratio represents 1 percentage-point increase in the corresponding variable.
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Table 3. County-Level (N = 210 Counties) Association Between Proportion of Residents With Access to Screening Within 30 Miles (in 2019) and Age-Adjusted Lung
Cancer Mortality Among Adults Aged ≥60 (in 2013–2017), Adjusted for Rurality (in 2019), and Demographic Characteristics (in 2013–2017), Missouri and Illinois
Model Parameter Change in Mortality per 100,000 Population, β (95% CI) [P Value]
Percentage of census block groups with access to lung cancer screening within 30 miles 0.04 (−0.15 to 0.23) [.68]
Degree of ruralitya
Large central metro 1 [Reference]
Large fringe metro 8.9 (−54.8 to 72.6) [.78]
Medium metro −8.7 (−74.5 to 57.0) [.79]
Small metro 3.4 (−58.3 to 65.2) [.91]
Micropolitan 2.7 (−60.9 to 66.3) [.93]
Noncore −4.6 (−68.5 to 59.3) [.89]
State
Illinois 1 [Reference]
Missouri −41.2 (−68.2 to −14.2) [.003]
Demographic characteristics
Percentage of population that reports smokingb 9.7 (4.6 to 14.9) [<.001]
Median annual household income, in thousands, $c 0.4 (−0.9 to 1.8) [.52]
Percentage of population aged ≥25 with a college degreec −2.7 (−3.9 to −1.5) [<.001]
Percentage of population that is Whitec 0.2 (−1.1 to 1.6) [.76]
Percentage of population that is African Americanc 0.8 (−1.1 to 2.7) [.42]
a Determined by National Center for Health Statistics (17).
b Determined by 2019 County Health Rankings (19).
c Determined by American Community Survey 5-year estimates (15).
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